Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
Authors:
- Alvaro Cobo-CalvoACAlvaro Cobo-Calvo
- María SepúlvedaMSMaría Sepúlveda
- Fabien RollotFRFabien Rollot
- Thais ArmanguéTAThais Armangué
- Anne RuizARAnne Ruiz
- Elisabeth MaillartEMElisabeth Maillart
- Caroline PapeixCPCaroline Papeix
- Bertrand AudoinBABertrand Audoin
- Helene ZephirHZHelene Zephir
- Damien BiottiDBDamien Biotti
- Jonathan CironJCJonathan Ciron
- Francoise Durand-DubiefFDFrancoise Durand-Dubief
Open Access
- 2 July 2019
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 16 (1) , 1-12
Abstract
Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease. This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment. Median age at onset was 34.1 years (range 18.0–67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1–89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20–0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab. In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD.Keywords
This publication has 41 references indexed in Scilit:
- MOG encephalomyelitis: international recommendations on diagnosis and antibody testingJournal of Neuroinflammation, 2018
- Clinical presentation and prognosis in MOG-antibody disease: a UK studyBrain, 2017
- Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndromeNeurology, 2017
- Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosisBrain, 2017
- Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopesJournal of Neurology, 2016
- Antibodies to MOG in adults with inflammatory demyelinating disease of the CNSNeurology Neuroimmunology & Neuroinflammation, 2015
- Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in childrenNeurology Neuroimmunology & Neuroinflammation, 2015
- Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the diseaseMultiple Sclerosis Journal, 2014
- Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein AntibodiesJAMA Neurology, 2014
- Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersNeurology, 2014